Global Bleeding Disorders Treatment Market, By Drug Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Others), Disease type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies), End Users (Clinics, Hospitals and Academic Institutions) – Industry Trends and Forecast to 2029
Market Analysis and Size
Although it is uncommon, haemophilia is the most well-known inherited bleeding disorder. Von Willebrand disease, the most common inherited bleeding disorder in the United States caused by clotting proteins, affects a large number of people. This disease affects both men and women and affects nearly 1% of the population in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately 400 newborns in the United States are affected by haemophilia each year.
Data Bridge Market Research analyses that the bleeding disorders treatment market is expected to reach the value of USD 11.65 billion by the year 2029, at a CAGR of 9.3% during the forecast period. The increase in awareness, demand, and preference for prophylactic treatment has resulted in an increase in the bleeding disorders treatment market.
Market Definition
The majority of bleeding disorders are inherited. Bleeding disorders occur when the body's ability to clot blood is impaired. A clot forms on the infected body part, which is made up of platelets and a specific type of blood cell. This clot prevents germs from entering the blood and also prevents blood from draining from the injured area. If the body is unable to produce the necessary number of clots, the infected area becomes a breeding ground for a variety of bacterial and viral diseases. In addition, severe injuries or infections can result in massive blood loss. Blood disorders can also occur as a result of a vitamin K deficiency or a low red blood cell count in the body.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drug Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Others), Disease type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies), End Users (Clinics, Hospitals and Academic Institutions)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France), Wellona Pharma (India), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan)
|
Bleeding disorders treatment Market Dynamics
Drivers
- The rise in the blood related disorders
As the prevalence of liver disorders, anaemia, and other blood coagulation disorders rises, so will the demand for bleeding disorders treatment.
The increase in the research and development activities and growing awareness
The growing awareness of the importance of treating various types of bleeding disorders is also creating lucrative bleeding disorders treatment market growth opportunities. Rising R&D initiatives for the treatment of various types of blood disorders will also broaden the scope for growth.
- Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market.
.Restraints/Challenges
The scarcity of skilled professionals and trained expertise will be a major impediment to the growth of the bleeding disorders treatment market. Medication costs will also slow the market's growth rate. Inadequate reimbursement policies will also limit the scope of growth.
This bleeding disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bleeding disorders treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Bleeding Disorders Treatment Market
In the best-case scenario, the COVID-19 pandemic has had a significant long-term positive impact on the bleeding disorders treatment market. Initially, there was a drop in the market in early 2020 as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased exponentially.
.Recent Development
- Novo Nordisk A/S launched Esperoct, an anti-hemophilic factor, in the United States in February 2020 for the treatment of adults and children with haemophilia A, i.e., to reduce and control bleeding episodes even during surgery.
Global Bleeding Disorders Treatment Market Scope
The bleeding disorders treatment market is segmented on the basis drug type, disease type, distribution channel and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug type
- Plasma-derived coagulation factor concentrates
- Recombinant coagulation factor concentrates
- Desmopressin
- Antifibrinolytics
- Fibrin sealants
- Others
On the basis of drug type, the bleeding disorders market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants and others. The plasma-derived coagulation factor concentrates are further sub-segmented into factor VIII, factor IX, factor for von willebrand disease and activated prothrombin complex concentrate. Recombinant coagulation factor concentrates is also sub-segmented into factor VIII, factor for von willebrand disease and factor IX.
End User
- Academic and research institutes
- Hospitals
- Clinics
On the basis of end users, the bleeding disorders treatment market is segmented into clinics, hospitals and academic institutions.
Disease type
- Hemophilia A
- Hemophilia B
- Von willebrand disease
- Liver disease
- Others
On the basis of disease type, the blood disorders treatment market is segmented into hemophilia A, hemophilia B, von willebrand disease, liver disease and others.
Bleeding Disorders Treatment Market Regional Analysis/Insights
The bleeding disorders treatment market is analysed and market size insights and trends are provided by country, drug type, disease type and end users as referenced above.
The countries covered in the bleeding disorders treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has the largest bleeding disorders treatment market and will maintain its dominance throughout the forecast period. This is due to the widespread use of prophylaxis treatment, particularly in countries such as the United States and Canada. Asia-Pacific, on the other hand, will experience the fastest growth due to a large patient pool and rising expenditure to improve healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The bleeding disorders treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bleeding disorders treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bleeding disorders treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Bleeding Disorders Treatment Market Share Analysis
The bleeding disorders treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bleeding disorders treatment market.
Some of the major players operating in the bleeding disorders treatment market are
- Johnson & Johnson Services, Inc. (U.S.)
- Novartis AG (Switzerland)
- Akorn Operating Company LLC (U.S.)
- Bausch & Lomb Incorporated (Canada)
- AbbVie Inc. (U.S.)
- Prestige Consumer Healthcare Inc. (U.S.)
- Théa Laboratories (France)
- Wellona Pharma (India)
- Bayer AG (Germany)
- Zydus Group
- Amneal Pharmaceuticals LLC (India)
- OASIS Medical (U.S.)
- Alcon (Switzerland)
- Santen Pharmaceutical Co., Ltd. (Japan)
SKU-